Tegoprazan - RaQualia Pharma/CJ Healthcare

Drug Profile

Tegoprazan - RaQualia Pharma/CJ Healthcare

Alternative Names: CJ 12420; RQ-00000004; RQ-4

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer CJ Cheiljedang Corp.; CJ HealthCare; RaQualia Pharma
  • Class Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux

Most Recent Events

  • 26 Oct 2017 CJ Healthcare plans a phase III trial for Helicobacter infections (In adults, In the elderly, Combination therapy) in South Korea (PO) in October 2017 (NCT03317223)
  • 24 Mar 2017 CJ HealthCare completes a phase III trial in Erosive oesophagitis in South Korea (PO, Tablet) (NCT03006874)
  • 01 Feb 2017 CJ HealthCare Corporation completes a phase I trial in Healthy volunteers in South Korea (PO) (NCT03011996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top